Alliancebernstein L.P. Decreases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Alliancebernstein L.P. trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 14.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,578,393 shares of the life sciences company's stock after selling 443,597 shares during the quarter. Alliancebernstein L.P. owned approximately 3.34% of Integra LifeSciences worth $58,478,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its position in shares of Integra LifeSciences by 10.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock valued at $23,759,000 after acquiring an additional 103,291 shares during the period. Systematic Financial Management LP lifted its position in Integra LifeSciences by 53.9% during the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock valued at $11,115,000 after purchasing an additional 214,272 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Integra LifeSciences by 5.5% during the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock valued at $9,603,000 after purchasing an additional 22,000 shares during the period. Leeward Investments LLC MA grew its holdings in Integra LifeSciences by 7.8% during the fourth quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company's stock valued at $9,197,000 after purchasing an additional 29,402 shares during the period. Finally, Norges Bank purchased a new stake in Integra LifeSciences in the fourth quarter worth about $8,967,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Price Performance

NASDAQ:IART traded up $0.01 on Monday, reaching $19.58. 770,282 shares of the company's stock traded hands, compared to its average volume of 1,045,530. The firm has a market cap of $1.51 billion, a PE ratio of -217.53, a P/E/G ratio of 0.73 and a beta of 1.24. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a 50-day simple moving average of $23.23 and a 200-day simple moving average of $22.35. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $34.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. During the same period in the previous year, the firm earned $0.89 EPS. The firm's revenue was up 11.5% compared to the same quarter last year. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.